CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study

被引:26
作者
Vansteenkiste, J. [1 ]
Reungwetwattana, T. [2 ]
Nakagawa, K. [3 ]
Cho, B. C. [4 ]
Cobo Dols, M. A. [5 ]
Cho, E. K. [6 ]
Bertolini, A. [7 ]
Bohnet, S. [8 ]
Zhou, C. [9 ]
Lee, K. H. [10 ]
Nogami, N. [11 ]
Okamoto, I. [12 ]
Leighl, N. [13 ]
Hodge, R. [14 ]
McKeown, A. [15 ]
Brown, A. P. [16 ]
Rukazenkov, Y. [17 ]
Ramalingam, S. [18 ]
机构
[1] Univ Hosp Leuven, Resp Oncol Unit Pulmonol, Leuven, Belgium
[2] Mahidol Univ, Fac Med, Div Med Oncol, Dept Med,Ramathibodi Hosp, Bangkok, Thailand
[3] Kindai Univ, Dept Med Oncol, Sch Med, Osaka, Japan
[4] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Div Med Oncol,Dept Internal Med, Seoul, South Korea
[5] Univ Hosp Virgen de la Victoria, Serv Oncol Med, Malaga, Spain
[6] Gachon Univ, Gil Med Ctr, Dept Internal Med, Div Hematol & Oncol, Incheon, South Korea
[7] Hosp Sondrio, Med Oncol Unit, Sondrio, Italy
[8] Univ Klin Schleswig Holstein, Med Klin 3, Campus Lubeck, Lubeck, Germany
[9] Tongji Univ, Dept Oncol, Pulm Hosp, Shanghai, Peoples R China
[10] Chungbuk Natl Univ Hosp, Div Med Oncol, Cheongju, South Korea
[11] Natl Hosp Org Shikoku Canc Ctr, Dept Thorac Oncol, Matsuyama, Ehime, Japan
[12] Kyushu Univ, Grad Sch Med Sci, Chest Dis Res Inst, Fukuoka, Japan
[13] Princess Margaret Canc Ctr, Med Oncol, Toronto, ON, Canada
[14] AstraZeneca UK Ltd, Biostat & Informat, Cambridge, England
[15] AstraZeneca UK Ltd, Biostatist & Informat, Melbourn, Royston, England
[16] AstraZeneca UK Ltd, Global Med Dept, Cambridge, England
[17] AstraZeneca UK Ltd, Res & Dev, Cambridge, England
[18] Emory Univ, Winship Canc Inst, Atlanta, AL USA
关键词
D O I
10.1093/annonc/mdx729.007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
LBA5
引用
收藏
页码:189 / 189
页数:1
相关论文
empty
未找到相关数据